…
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Immunome, Inc. is a clinical-stage biotechnology company that discovers and develops human antibody therapeutics using a memory B‑cell discovery platform focused on oncology and immune-driven diseases. Long-term growth drivers include advancement of clinical-stage candidates, broader application of its antibody discovery technology and potential partnerships or licenses that could accelerate development. Investors may find exposure to a pipeline that could generate value from clinical milestones and technology licensing of interest.
Principal investment risks include clinical and regulatory failure for lead candidates, ongoing cash burn and the need for additional financing, and intense competition from larger, better-funded biologics developers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -36.90M | -24.71M | -17.84M | -10.44M | -7.84M |
| Net income | -37.51M | -24.47M | -17.12M | -10.55M | -7.84M |
| Selling general administrative | 13.63M | 11.09M | 4.78M | 1.52M | 0.87M |
| Reconciled depreciation | 0.63M | 0.76M | 0.76M | 0.61M | 0.52M |
| Ebit | -36.90M | -25.20M | -13.02M | -10.35M | -7.70M |
| Ebitda | -36.27M | -24.70M | -12.26M | -9.72M | -7.18M |
| Depreciation and amortization | 0.63M | 0.50M | 0.76M | 0.62M | 0.52M |
| Non operating income net other | 0.01M | - | - | - | - |
| Operating income | -36.90M | -25.20M | -12.26M | -10.35M | -7.74M |
| Other operating expenses | 36.90M | 25.20M | 12.26M | 10.35M | 7.74M |
| Interest expense | 0.01M | 0.01M | 0.04M | 0.11M | 0.14M |
| Interest income | - | - | 0.00M | 0.01M | 0.04M |
| Net interest income | 0.01M | -0.01M | -0.04M | -0.10M | -0.10M |
| Income tax expense | 0.62M | -0.24M | -0.72M | 0.11M | 0.04M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 36.90M | 25.20M | 12.26M | 10.35M | 7.74M |
| Total other income expense net | 0.01M | 0.49M | -5.58M | -0.10M | -0.10M |
| Net income from continuing ops | -36.90M | -24.71M | -17.84M | -10.44M | -7.84M |
| Net income applicable to common shares | -37.52M | -24.71M | -17.84M | -10.44M | -7.84M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 148.54M | 24.05M | 57.92M | 44.52M | 5.06M |
| Other current assets | 6.27M | 2.33M | 7.41M | 3.13M | 0.58M |
| Total liab | 28.66M | 7.39M | 9.74M | 3.18M | 40.69M |
| Total stockholder equity | 119.88M | 16.65M | 48.19M | 41.34M | -35.63M |
| Deferred long term liab | - | 0.33M | 0.33M | - | - |
| Other current liab | 7.71M | 4.64M | 6.65M | 1.37M | 0.67M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -222.81M | -116.00M | -79.11M | -54.39M | -36.56M |
| Other liab | - | - | 0.01M | 0.01M | 0.02M |
| Other assets | 0.00M | 0.43M | 0.43M | 0.10M | 0.24M |
| Cash | 98.68M | 20.32M | 49.23M | 39.77M | 2.54M |
| Total current liabilities | 21.83M | 7.33M | 9.73M | 3.04M | 1.67M |
| Current deferred revenue | 10.49M | - | - | - | - |
| Net debt | -97.03M | -20.03M | -49.23M | -39.15M | -1.98M |
| Short term debt | 0.31M | 0.29M | - | 0.48M | 0.45M |
| Short long term debt | - | - | - | 0.48M | 0.21M |
| Short long term debt total | 1.65M | 0.29M | - | 0.61M | 0.56M |
| Other stockholder equity | 342.66M | 132.65M | 127.29M | 95.74M | 0.93M |
| Property plant equipment | - | 0.68M | 0.85M | 1.53M | 1.70M |
| Total current assets | 144.70M | 22.65M | 56.64M | 42.89M | 3.12M |
| Net tangible assets | - | 16.65M | 48.19M | 41.34M | -35.63M |
| Short term investments | 39.46M | - | - | - | - |
| Net receivables | 0.29M | 0.85M | 4.31M | 0.90M | - |
| Long term debt | - | - | - | 0.13M | 0.11M |
| Inventory | - | -0.85M | -4.31M | - | - |
| Accounts payable | 3.31M | 2.40M | 3.08M | 1.19M | 0.55M |
| Accumulated other comprehensive income | 0.02M | - | -57.92M | -44.52M | -1.52M |
| Common stock total equity | - | 0.00M | - | 0.00M | - |
| Retained earnings total equity | - | -116.00M | - | -54.39M | - |
| Non currrent assets other | 0.10M | 0.43M | 0.43M | 0.10M | 0.24M |
| Non current assets total | 3.84M | 1.40M | 1.29M | 1.63M | 1.94M |
| Capital lease obligations | 1.65M | 0.29M | - | 0.00M | 0.24M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.25M | -0.08M | -0.59M | -0.23M | -0.23M |
| Change to liabilities | -2.83M | 1.78M | 0.50M | 0.07M | 0.15M |
| Total cashflows from investing activities | -0.25M | -0.08M | -0.59M | -0.23M | -0.23M |
| Net borrowings | 0.49M | -0.11M | 0.05M | -0.61M | -0.55M |
| Total cash from financing activities | 0.03M | 27.77M | 49.94M | 10.77M | -0.55M |
| Change to operating activities | 2.92M | 1.00M | -1.71M | 0.14M | -0.25M |
| Net income | -36.90M | -24.71M | -17.84M | -10.44M | -7.84M |
| Change in cash | -28.91M | 9.46M | 37.22M | 0.94M | -8.19M |
| Begin period cash flow | 49.33M | 39.87M | 2.64M | 1.70M | 9.89M |
| End period cash flow | 20.42M | 49.33M | 39.87M | 2.64M | 1.70M |
| Total cash from operating activities | -28.69M | -18.23M | -12.13M | -9.60M | -7.41M |
| Issuance of capital stock | 0.00M | 27.23M | 55.90M | 4.62M | 0.00M |
| Depreciation | 0.63M | 0.76M | 0.76M | 0.61M | 0.52M |
| Sale purchase of stock | 0.03M | - | 55.87M | -0.04M | 0.00M |
| Other cashflows from financing activities | -0.25M | 0.66M | 5.54M | 11.42M | -0.23M |
| Change to netincome | 5.33M | 2.95M | 6.16M | 0.02M | 0.02M |
| Capital expenditures | 0.25M | 0.08M | 0.59M | 0.23M | 0.23M |
| Cash flows other operating | 5.28M | - | -2.41M | - | - |
| Cash and cash equivalents changes | -28.91M | - | 37.22M | - | - |
| Change in working capital | 2.24M | 2.78M | -1.21M | 0.21M | -0.10M |
| Stock based compensation | 5.33M | 3.45M | 0.62M | 0.01M | 0.01M |
| Other non cash items | - | 0.00M | -0.00M | 0.00M | 0.01M |
| Free cash flow | -28.94M | -18.30M | -12.72M | -9.83M | -7.63M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IMNM Immunome Inc |
- -% |
15.69 | - | - | 87.64 | 10.26 | 77.74 | -38.92 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
| Name | Title | Year Born |
|---|---|---|
| Dr. Purnanand Duddu Sarma Ph.D. | Pres, CEO & Director | 1965 |
| Ms. Corleen M. Roche | Chief Financial Officer | 1966 |
| Dr. Dennis H. Giesing Ph.D. | Chief Devel. Officer | 1952 |
| Dr. Scott K. Dessain M.D., Ph.D. | Co-founder & Chairman of the Scientific Advisory Board | NA |
| Dr. Matthew K. Robinson Ph.D. | Chief Technology Officer | NA |
| Dr. Michael J. Morin Ph.D. | Chief Scientist | 1955 |
| Ms. Sandra G. Stoneman Esq. | Chief Legal Officer, Gen. Counsel & Corp. Sec. | 1973 |
| Mr. Robert Lapetina | VP of Fin. & Corp. Controller | NA |
| Dr. Clay B. Siegall Ph.D. | President, CEO & Chairman | 1961 |
| Mr. Max Rosett | Interim CFO & Executive VP of Operations | 1990 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.